Levodopa in the treatment of Parkinson's disease: a consensus meeting

Mov Disord. 1999 Nov;14(6):911-3. doi: 10.1002/1531-8257(199911)14:6<911::aid-mds1001>3.0.co;2-h.

Authors

Y Agid¹, E Ahlskog, A Albanese, D Calne, T Chase, J De Yebenes, S Factor, S Fahn, O Gershanik, C Goetz, W Koller, M Kurth, A Lang, A Lees, P Lewitt, D Marsden, E Melamed, P P Michel, Y Mizuno, J Obeso, W Oertel, W Olanow, W Poewe, P Pollak, E Tolosa, et al.

Affiliation

¹ INSERM U 289 & Fédération de Neurologie, Hôpital de la Salpêtrière-47, Paris, France.

PMID: 10584663
DOI: 10.1002/1531-8257(199911)14:6<911::aid-mds1001>3.0.co;2-h

No abstract available

Publication types

Consensus Development Conference
Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antiparkinson Agents / administration & dosage*
Antiparkinson Agents / adverse effects
Brain / drug effects
Cell Death / drug effects
Dose-Response Relationship, Drug
Drug Administration Schedule
Humans
Levodopa / administration & dosage*
Levodopa / adverse effects
Parkinson Disease / drug therapy*

Substances

Antiparkinson Agents
Levodopa